Efficacy evaluation of low-dose aspirin in IVF/ICSI patients evidence from 13 RCTs: A systematic review and meta-analysis

    loading  Checking for direct PDF access through Ovid



We conducted a systematic review and meta-analysis of existing literature to evaluate the different outcomes of low-dose aspirin on patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), including clinical pregnancy rate, implantation rate, live birth rate, miscarriage rate, fertilization rate, number of oocytes retrieved, and so forth.


Electronic databases including PubMed, MEDLINE, and Embase were searched between 1997 and March 2016 to identity eligible studies. The following comparisons between treatment groups were included: aspirin versus placebo; aspirin versus control group; aspirin versus aspirin + prednisolone + control.


Thirteen randomized controlled trials which included 3104 participants were selected. There were no significant differences in implantation rate (RR = 1.15; 95% CI = 0.78–1.70), live birth rate (RR = 1.06; 95% CI = 0.93–1.21), miscarriage rate (RR = 1.28; 95% CI = 0.93–1.77), fertilization rate (RR = 0.91; 95% CI = 0.75–1.11), and endometrial thickness (WMD = 0.15; 95% CI = −0.38–0.67). But the research showed that aspirin treatment may improve the clinical pregnancy rate (RR = 1.16; 95% CI = 1.04–1.28) compared to placebo or no treatment, and reduce the number of oocytes retrieved (WMD = −0.68; 95% CI = −0.91–0.46).


Our findings suggest that low-dose aspirin may improve the pregnancy rate in IVF/ICSI, with the recommended clinical use dose of 100 mg/day. Considering the limitation of included studies, further well-designed large-scaled RCTs are necessary to clarify whether aspirin may improve assisted reproduction outcomes in IVF/ICSI patients.

Related Topics

    loading  Loading Related Articles